Role of the Serotonin 5-HT2A Receptor in Learning John A. Harvey Learning & Memory, 2003, 355-362 www.learnmem.org http://www.learnmem.org/cgi/doi/10.1101/lm.60803. This study reviews the role of the serotonin 5-HT2A receptor in learning as measured by the acquisition of the rabbit’s classically conditioning nictitating membrane response, a component of the eyeblink response. Agonists at the 5-HT2A receptor including LSD (d-lysergic acid diethylamide) enhanced associative learning at doses that produce cognitive effects in humans. Some antagonists such as BOL (d-bromolysergic acid diethylamide), LY53,857, and ketanserin acted as neutral antagonists in that they had no effect on learning, whereas others (MDL11,939, ritanserin, and mianserin) acted as inverse agonists in that [...]
Lire la suiteN-Arachidonoyl Dopamine : A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities Urszula Grabiec and Faramarz Dehghani Cannabis and Cannabinoid Research, 2017, 2, (1), 183-196 DOI: 10.1089/can.2017.0015 Abstract N-arachidonoyl dopamine (NADA) is a member of the family of endocannabinoids to which several other N-acyldopamines belong as well. Their activity is mediated through various targets that include cannabinoid receptors or transient receptor potential vanilloid (TRPV)1. Synthesis and degradation of NADA are not yet fully understood. Nonetheless, there is evidence that NADA plays an important role in nociception and inflammation in the central and peripheral nervous system. The TRPV1 receptor, for which NADA is a [...]
Lire la suiteCannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults David L. Arndt and Harriet de Wit Cannabis and Cannabinoid Research, 2017, 2, (1), 105-113 DOI: 10.1089/can.2017.0014 Abstract Introduction : Cannabidiol (CBD) is a nonpsychoactive constituent of whole plant cannabis that has been reported to reduce anxiety-like behaviors in both pre-clinical and human laboratory studies. Yet, no controlled clinical studies have demonstrated its ability to reduce negative mood or dampen responses to negative emotional stimuli in humans. The objective of this study was to investigate the effects of CBD on responses to negative emotional stimuli, as a model for its potential anxiety-reducing effects. Materials and [...]
Lire la suiteThe Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders Franz X. VOLLENWEIDER & Michael KOMETER Nature Reviews Neuroscience, 2010, 11, (9), 642-51 DOI: 10.1038/nrn2884 Abstract After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical [...]
Lire la suiteThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future Robin L Carhart-Harris and Guy M Goodwin Neuropsychopharmacology, 2017, 42, 2105–2113 doi:10.1038/npp.2017.84; published online 17 May 2017 Plant-based psychedelics, such as psilocybin, have an ancient history of medicinal use. After the first English language report on LSD in 1950, psychedelics enjoyed a short-lived relationship with psychology and psychiatry. Used most notably as aids to psychotherapy for the treatment of mood disorders and alcohol dependence, drugs such as LSD showed initial therapeutic promise before prohibitive legislature in the mid-1960s effectively ended all major psychedelic research programs. Since the early 1990s, there has been a steady [...]
Lire la suitePredicting Responses to Psychedelics : A Prospective Study Eline C. H. M. Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E. Daws, Adam D. G. Hampshire, Romy Lorenz and Robin L. Carhart-Harris Frontiers in Pharmacology, 2018 doi: 10.3389/fphar.2018.00897 Abstract Responses to psychedelics are notoriously difficult to predict, yet significant work is currently underway to assess their therapeutic potential and the level of interest in psychedelics among the general public appears to be increasing. We aimed to collect prospective data in order to improve our ability to predict acute- and longer-term responses to psychedelics. Individuals who planned to take a [...]
Lire la suiteRetrouvez l’ensemble des interventions des 24es Rencontres du RESPADD - GRECC : Utilisation cliniques des cannabinoïdes, juin 2019 Sarah LEJCZAK "Utilisation du Marinol en France : enquête auprès des prescripteurs" Roland TUBIANA et Fabienne CABY "Infection VIH et cannabinoïdes, état des lieux et pistes en recherche clinique" Allison McKIM : "Addicted to rehab : race, gender and drugs in the era of mass incarceration" Fabrice Olivet : "Races et drogues, les termes du sujet" François BAILLY : "Le cannabidiol en traitement "anti-addictif" chez les patients alcooliques : l'étude Caramel" Julien AZUAR "Usage de CBD et maladie psychiatrique" Pierre CHAMPY : "Cannabis sativa, plante médicinale en France ?" Jean-Michel [...]
Lire la suite'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape, October 20, 2017 https://www.medscape.com/viewarticle/887384 Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at [...]
Lire la suiteNovel insights into mitochondrial molecular targets of iron-inducedneurodegeneration: Reversal by cannabidiol Vanessa Kappel da Silva, Betânia Souza de Freitas, Victória Campos Dornelles,Luiza Wilges Kist, Maurício Reis Bogoc, Milena Carvalho Silvad, Emílio Luiz Streck, Jaime Eduardo Hallak, Antônio Waldo Zuardib,e, José Alexandre S. Crippab,e,Nadja Schrödera Brain Research Bulletin, 2018, 139, 1–8 https://doi.org/10.1016/j.brainresbull.2018.01.014 ABSTRACT Evidence has demonstrated iron accumulation in specific brain regions of patients suffering from neurodegen-erative disorders, and this metal has been recognized as a contributing factor for neurodegeneration. Using anexperimental model of brain iron accumulation, we have shown that iron induces severe memory deficits thatare accompanied by oxidative stress, increased apoptotic markers, and decreased [...]
Lire la suiteThe neuroprotection of cannabidiol against MPP+-induced toxicity inPC12 cells involves trkA receptors, upregulation of axonal and synapticproteins, neuritogenesis, and might be relevant to Parkinson's disease Neife Aparecida Guinaim Santos, Nádia Maria Martins, Flávia Malvestio Sisti, Laís Silva Fernandes, Rafaela Scalco Ferreira, Regina Helena Costa Queiroz, Antônio Cardozo Santos Toxicology in Vitro, 2015, 30, 231–240. http://dx.doi.org/10.1016/j.tiv.2015.11.004 a b s t r a c t Cannabidiol (CBD) is a non-psychoactive constituent of Cannabis sativa with potential to treat neurodegenerative diseases. Its neuroprotection has beenmainly associated with anti-inflammatory and antioxidant events; however, other mechanisms might be involved. We investigated the involvement of neuritogenesis, NGF receptors (trkA), NGF, and [...]
Lire la suite